Halogenated Pyrrolopyrimidines with Low MIC on *Staphylococcus aureus* and Synergistic Effects with an Antimicrobial Peptide

Cecilie Elisabeth Olsen 1, Fredrik Heen Blindheim 1, Caroline Krogh Søgaard 2, Lisa Marie Røst 3, Amanda Holstad Singleton 2, Olaug Elisabeth Torheim Bergum 1, Per Bruheim 1, Marit Otterlei 2, Eirik Sundby 4 and Bård Helge Hoff 1,*

1 Department of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway; cecilie.e.olsen@ntnu.no (C.E.O.); fredrik.h.blindheim@ntnu.no (F.H.B.)
2 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway; caroline.d.sogaard@ntnu.no (C.K.S.); amanda.singleton@ntnu.no (A.H.S.); olaug.e.bergum@ntnu.no (O.E.T.B.); marit.otterlei@ntnu.no (M.O.)
3 Department of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway; lisa.m.rost@ntnu.no (L.M.R.); perbruheim@ntnu.no (P.B.)
4 Department of Material Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway; eirik.sundby@ntnu.no
* Correspondence: bard.h.hoff@ntnu.no

**Abstract:** Currently, there is a world-wide rise in antibiotic resistance causing burdens to individuals and public healthcare systems. At the same time drug development is lagging behind. Therefore, finding new ways of treating bacterial infections either by identifying new agents or combinations of drugs is of utmost importance. Additionally, if combination therapy is based on agents with different modes of action, resistance is less likely to develop. The synthesis of 21 fused pyrimidines and a structure-activity relationship study identified two 6-aryl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amines with potent activity towards *Staphylococcus aureus*. The MIC-value was found to be highly dependent on a bromo or iodo substitution in the 4-benzylamine group and a hydroxyl in the meta or para position of the 6-aryl unit. The most active bromo and iodo derivatives had MIC of 8 mg/L. Interestingly, the most potent compounds experienced a four-fold lower MIC-value when they were combined with the antimicrobial peptide betatide giving MIC of 1–2 mg/L. The front runner bromo derivative also has a low activity towards 50 human kinases, including thymidylate monophosphate kinase, a putative antibacterial target.

**Keywords:** antibacterial; pyrrolopyrimidines; synergistic effect; halogenated antibiotic

### 1. Introduction

Due to the rise in antimicrobial resistance, there is an urgent need of novel antibiotics preferably acting on new biological targets. Moreover, if therapy is based on two or more agents with differing modes of action, resistance is less likely to develop. Several studies have shown a synergistic effect between antimicrobial peptides (AMP) and traditional antibiotics, both in lowering the minimum inhibitory concentration (MIC) and overcoming resistance [1–8]. Synergistic effects can happen by several mechanisms, such as increased uptake [3] or though changes in metabolic nucleotide demand which possibly makes bacteria more sensitive to nucleotide anti-metabolites [6]. We, therefore, wanted to explore this avenue and selected betatide, a cell-penetrating peptide that targets the bacterial DNA sliding clamp [9], which has previously demonstrated substantial MIC lowering when it is combined with classical antibiotics [10].

As a starting point to discover new low molecular weight antibiotics, we selected PKI-166 (Scheme 1), a pyrrolopyrimidine that was previously investigated as an anti-
Finally, we wanted to explore the effect of halogen insertion on antibacterial activity. These elements are rarely found in drugs besides X-ray contrast agents [24] and the only heavy halogen-containing drug on the WHO 2021 AWaRe list [25] was brodimoprim [26], which is not in current clinical use [27]. One reason that brominated and iodinated drugs are rare could be that hit selection metrics disfavor these as starting points in drug development campaigns. However, heavier halogen-containing antibiotics have been described from many different origins such as natural products [28,29], by microbial cultivation with halogen salts, [30], and synthetic origin [31–34]. Brominated tryptophanes and tyrosines are also frequently used in peptides with antibiotic effects [35]. Increased activity and stability of heavy halogen-modified peptide antibiotics has also been reported [36]. This effect could be due to the altered size and concomitant change in van der Waals interactions, but could also be caused by directional interactions with the target through halogen bonding [37,38].

Herein we describe a structure-activity relationship study which shows that increased activity and selectivity can be achieved by the insertion of heavy halogens (bromine and iodine). Further, the most active agents in combination with betatide showed a clear synergetic effect towards S. aureus. In the search of antibacterial targets, an enzymatic assay towards E. coli and human TMPK was performed. Additionally, the most active derivative was evaluated toward a panel of 50 human kinases to identify off-targets.

2. Results
2.1. Study Design

Our previous study attempting to identify E. coli TMPK inhibitors revealed that the previously discontinued epidermal growth factor receptor (EGFR) inhibitor PKI-166 [10,12] had an IC$_{50}$ of 15 µM against E. coli TMPK (Scheme 1). We, therefore, wanted to develop this lead further by aiming to (i) reduce the EGFR inhibitory activity, (ii) improve antibacterial activity, and possibly (iii) develop a better structure-activity relationship (SAR) understanding.

From our previous EGFR studies, we knew that the inhibitory activity of this kinase was very sensitive to substitution of the amine part [10]. Therefore, we first investigated variations of the 4-amino group, which led to the discovery that $p$-bromo substitution (compound 5) had improved antibacterial activity with a concomitant reduction in EGFR activity. Then, further SAR investigation was performed by modifying the 6-aryl group.
and exchanging the NH in the pyrrolopyrimidine with a sulphur giving the corresponding thienopyrimidine.

In contrast to our previous studies on TMPK inhibitors [10,12] where enzymatic assays were employed, herein we have chosen to assay the compounds in culture to ensure that the cell penetrating compounds are identified. *E. coli* was selected as a model of Gram-negative bacteria and *S. aureus* for Gram-positive bacteria. Finally, we planned to investigate the synergetic effect when combining a small molecular antibiotic with antimicrobial peptides.

### 2.2. Synthesis of Fused Pyrimidines

The synthesis in the pyrrolopyrimidine series started from 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine, which was protected with *N*-(trimethyl)silylethoxymethyl (SEM) and selectively iodinated in the 6-position. This yielded building block 22 with two “handles” that could easily be modified in Pd-catalyzed cross-coupling reactions or nucleophilic aromatic substitutions. Compound 22 was then used to construct all pyrrolopyrimidine derivatives.

In the first route (Scheme 2), we started with a Suzuki coupling on 22 with 4-hydroxyphe nyl boronic acid as coupling partner and Pd$_2$(dba)$_3$ as a catalyst. This led to a high selectivity for the mono 6-arylated 23 over the 4,6-diarylated byproduct (19:1 ratio). Yields in the range of 52–71% were obtained. In most cases the aminations at C-4 proceeded smoothly but required significant amounts of co-base when the amine HCl salts were used. Acid catalyzed reactions were unsuccessful. The removal of the SEM-protecting group was then achieved by a two-step protocol using trifluoroacetic acid (TFA) and NaHCO$_3$ in a previously established procedure [12]. This led to a library of pyrrolopyrimidines in 13-98% yields. Some debenzylation occurred for the more electron-rich amines, and an overall high crystallinity complicated chromatographic purification. We found purification by reversed phase chromatography to work better than normal phase in most cases. An alternative variant of this route was also evaluated by utilizing the methoxy analog 24. However, purification after Suzuki coupling was found to be more difficult due to coelution, and the double deprotection at the end both involved the rather harsh reagent boron tribromide and was challenging to monitor by HPLC and $^1$H NMR spectroscopy.

To study the antibacterial effect of varying the 6-aryl substitution pattern, we used the route that is shown in Scheme 3. Here, amination of 22 with the most active amine ((R)-1-(4-bromophenyl)ethan-1-amine) gave the advanced building block 34 in 91% yield,

---

**Scheme 2.** Synthesis of the pyrrolopyrimidines 1–10.

To study the antibacterial effect of varying the 6-aryl substitution pattern, we used the route that is shown in Scheme 3. Here, amination of 22 with the most active amine ((R)-1-(4-bromophenyl)ethan-1-amine) gave the advanced building block 34 in 91% yield,
see Scheme 3. In the following chemoselective Suzuki cross-coupling, six different palladium catalysts were evaluated, of which Pd(dppf)Cl₂ was found to be the most selective. Depending on the nature of the substitution and scale, the selectivity varied between 3:1 and 19:1 in favor of the mono-arylated vs. the diarylated by-product and yields in the range of 26–72% were obtained. Finally, SEM deprotection afforded a series of substituted 6-aryl pyrrolopyrimidines in 36–78% yield. The aniline derivative 15 was made by reduction of the nitro analogue 14.

Scheme 3. Synthesis of the pyrrolopyrimidines 10–20.

Finally, the effect of substituting the pyrrole nitrogen was investigated by the construction of two thienopyrimidine derivatives. Here, 6-bromo-4-chloro-thienopyrimidine was coupled with 4-methoxyphenyl boronic acid to yield building block 44, which was aminated with (R)-1-(4-bromophenyl)ethan-1-amine to give thienopyrimidine 20, containing a para-methoxy group, see Scheme 4. Demethylation with BBr₃ yielded the corresponding phenolic derivative 21.

Scheme 4. Synthesis of thienopyrimidines 20 and 21.

2.3. Evaluation of Antibiotic Activity

2.3.1. Variation of the 4-Amino Group

Our previous efforts at targeting TMPK using enzyme assays have, unfortunately, arrived at compounds that are inactive in culture experiments [12,39]. In this study, we have, therefore, altered our strategy and used minimal inhibitory concentration assays to identify and improve antibacterial agents. A total of 10 pyrrolopyrimidines with variation of the 4-amino group were assayed for their MIC in E. coli (MG1655) and S. aureus (ATCC29213) using the broth microdilution method [40]. Subsequently, the compounds were also counter-screened for their inhibition of human EGFR. The results are summarized in Table 1.
Table 1. Minimum inhibitory concentration (MIC) in E. coli and S. aureus and the inhibition of human EGFR for the pyrrolopyrimidines with varied 4-amino group.

| Comp. | E. coli MIC [mg/L] 1 | S. aureus MIC [mg/L] 1 | Human EGFR [%] 2 |
|-------|----------------------|------------------------|------------------|
| 1     | >128                 | 64                     | 100              |
| 2     | >128                 | 16                     | 91               |
| 3     | >128                 | >128                   | 92               |
| 4     | >128                 | 16                     | 91               |
| 5     | >128                 | 8                      | 81               |
| 6     | >128                 | 8                      | 43               |
| 7     | >128                 | 16                     | 89               |
| 8     | >128                 | >128                   | 67               |
| 9     | >128                 | >128                   | ND 3            |
| 10    | >128                 | >128                   | 16               |

1 MIC values were determined using the broth microdilution method [40]. 2 Enzymatic EGFR inhibition assay. The compounds were tested towards EGFR using ThermoFisher Z-lyte technology at a concentration of 100 nM. The ATP concentration was qual to KM. 3 Not determined.

Given its activity towards E. coli TMPK in enzymatic studies [12], it was unfortunate that 1 and all the other derivatives did not possess any activity towards E. coli in culture. This is probably due to the more complex cell wall of Gram-negative bacteria and, therefore, lack of cellular uptake. On the other hand, compound 1 had an MIC of 64 mg/L towards the Gram-positive S. aureus. Whereas the corresponding 4-fluoro derivative 3 was inactive, increased potency was seen for the other para-substituted derivatives and an MIC of 8 mg/L towards S. aureus was seen for the para-bromo and para-iodo derivatives 5 and 6. The MIC was increased to 16 mg/L with a meta-bromine substituent, which might indicate a steric clash. Interestingly, the removal of the methyl group at the stereocenter (comp. 8), changing the stereochemistry (comp. 9) or adding an N-methyl (comp. 10) abolished all activity towards S. aureus. The relatively large variation in the MIC values upon these minor structural changes strongly suggests that the compounds act on an intracellular target, rather than having some unspecific effect on the bacterial cell membrane. Finally, the enzymatic assay towards human EGFR showed that the activity dropped when the size of the 4-aryl substituent increased, in line with our earlier assumption.
2.3.2. Variation of the 6-Aryl Group and the 7-Heteroatom

In the second series of potential inhibitors, we varied the 6-aryl group and the heteroatom of the five-membered heterocycle. The results are summarized in Table 2. The pyrrolopyrimidines 11–18 were all inactive towards both *E. coli* and *S. aureus*, but the *meta*-hydroxy derivative 19 had an MIC of 16 mg/L towards *S. aureus*. Further, whereas the methoxy substituted thienopyrimidine 20 had no activity, the corresponding *para*-hydroxy derivative 21 had an MIC of 32 mg/L. This clearly shows the important role of both the pyrrole NH and the *para* or *meta*-hydroxy group for the activity of this compound class.

Table 2. Minimum inhibitory concentration (MIC) in *E. coli* and *S. aureus* and the inhibition of human EGFR for the 6-aryl substituted pyrrolopyrimidine and thienopyrimidine analogs.

| Comp. | 6-Aryl | X  | *E. coli* MIC [mg/L] | *S. aureus* MIC [mg/L] | Human EGFR [% Inhibition] |
|-------|--------|----|---------------------|------------------------|--------------------------|
| 11    |       | NH | >128                | >128                   |                          |
| 12    |       | NH | >128                | >128                   | 66                       |
| 13    |       | NH | >128                | >128                   | 58                       |
| 14    |       | NH | >128                | >128                   | 33                       |
| 15    |       | NH | >128                | >128                   | 90                       |
| 16    |       | NH | >128                | >128                   | 42                       |
| 17    |       | NH | >128                | >128                   | 85                       |
| 18    |       | NH | >128                | >128                   | 80                       |
| 19    |       | NH | >128                | 16                     | 73                       |
| 20    | S      |    | >128                | >128                   | 12                       |
| 21    | S      |    | >128                | 32                     | 5                        |

1 MIC values were determined using the broth microdilution method [40]. 2 Enzymatic EGFR inhibition assay. The compounds were tested towards EGFR using ThermoFisher Z-lyte technology at a concentration of 100 nM. The ATP concentration was equal to KM.

2.3.3. Combination Studies with the Antimicrobial Peptide Betatide

The derivatives with an MIC < 64 mg/L were then subjected to additional MIC profiling towards *S. aureus* in combination with the antimicrobial peptide betatide, which has demonstrated antimicrobial effects in multiple multi-resistant bacterial strains [9,10]. The concentration of betatide was 8 mg/L, which corresponds to half the MIC concentration.

The results that are summarized in Table 3 showed that all the compounds experience increased activity and lower MIC when they are combined with betatide. The activity trend
roughly followed that which was seen for the single agents with the para-bromo and the para-iodo derivatives 5 and 6 being most potent.

Table 3. Minimum inhibitory concentration (MIC) towards *S. aureus* as single agent and in combination with peptide betatide.

| Comp. | 4-Amino Group | Scaffold | Single Comp. MIC [mg/L] | Combination with Betatide MIC [mg/L] |
|-------|---------------|----------|-------------------------|-------------------------------------|
| 1     |               | A        | 64                      | 8                                   |
| 2     |               | A        | 16                      | 8                                   |
| 4     |               | A        | 16                      | 4                                   |
| 5     |               | A        | 8                       | 1                                   |
| 6     |               | A        | 8                       | 2                                   |
| 7     |               | A        | 16                      | 4                                   |
| 19    |               | B        | 8                       | 2                                   |
| 21    |               | C        | 32                      | 4                                   |
|       |               |          |                         | Betatide 16                          |

2.3.4. Structure-Activity Relationship

The SAR information that was gathered is shown in Figure 1. Crucial for activity is a phenolic group in *para* or *meta* position of the 6-aryl group. The other substitution patterns that were tested resulted in no activity.

Although some activity is retained when the heteroatom in the five membered ring is substituted for sulphur, the corresponding pyrrolopyrimidines were more active. For the 4-amino group, a single methyl group in R₃ switches activity on and off. Thus, R₂ should be a methyl and R₃ must be a hydrogen. Other alkyls as R₂ were not tested. For the R₁-substituents at the benzylamine there was a preference for *para*-substitution by bromine and iodine. Further studies on the variation of the R₁ group must be performed to verify if the increase in the activity is caused by the halogens or if it is purely a size effect.
2.4. Kinase Off-Targets and Mechanistic Studies

Based on the similarity of 5 with structures in our previous study [12], one could assume the bromo derivative 5 to be a TMPK inhibitor. Unfortunately, an assay towards S. aureus TMPK was not available. Instead, compound 5 was assayed towards the human and E. coli variant of TMPK, see Figure 2. Compound 5 had an IC$_{50}$ of 5 µM towards E. coli TMPK and >100 µM towards the human variant. Thus, even though the sequence similarity is not high (34% by Protein Blast), TMPK could be a target also in S. aureus as the folding (see Figure S41 in Supplementary Materials) and important residues in the catalytic domains: LID, p-loop, and the DRX motif are highly conserved [41,42].

Figure 1. Structure-activity relationship that was identified for the inhibitors in this study. The green color denotes high activity, black medium, and red low.

Figure 2. IC$_{50}$ curves for inhibition of E. coli (blue circles) and human (green squares) TMPK for compound 5.

As the starting point of this study was the EGFR inhibitor PKI-166 (1), there is an obvious risk of kinase off-target effects for the bromo derivative 5. Therefore, we profiled 5 towards a panel of 50 human kinases. The most inhibited kinase was EGFR (91% inhibition at 500 nM test concentration), while very low inhibition was seen towards all the other kinases that were tested. This is shown in Figure 3. A follow up IC$_{50}$ measurement towards EGFR showed PKI-166 (1) to have IC$_{50}$ < 1 nM, while 5 had an IC$_{50}$ of 25 nM. Based on our previous experience [43,44], it is assumed that the EGFR inhibiting activity of 5 is too low to cause in vivo effects.
We found a combinatory effect with some, but not all, of both types of antibiotics (data not shown). This suggests that the combinatory effects between the fused pyrimidines and betatide are due to intracellular mechanisms and not an increased uptake of the compounds. Further studies to explore the molecular mechanisms behind the combinatory effects are ongoing.

3. Experimental Section

3.1. Chemicals and Materials

All the reagents and solvents used were purchased from Merck (Rahway, NJ, USA), VWR (Sugar Land, TX, USA) or Alpha Aesar (Ward Hill, MA, USA) and used without further purification. Compound 3 was previously prepared by Kaspersen et al. [45]. The reactions that were sensitive to moisture or oxygen were conducted under an N₂ atmosphere using oven-dried glassware and solvents that were dried over molecular sieves for 24 h or collected from an MBraun SPS-800 solvent purifier. For flash chromatography, different stationary phases were used: for normal phase, silica-gel (40–63 µm particle size) purchased from VWR, prepackaged cartridges (Biotage Sfär Silica D Duo 60 µm and Biotage Sfär Silica HC D, 20 µm, Biotage, Uppsala, Sweeden, and Alumina, neutral, Brockmann I (58 Å pore size) that was purchased from Merck. For reversed phase flash chromatography prepackaged cartridges from Biotage (Biotage Sfär C18 D, 100 Å, 30 µm, 12 g) were used.

3.2. Analysis and Characterization

Accurate mass determination in positive and negative mode was performed on a “Synapt G2-S” Q-TOF instrument from Waters™ (Milford, MA, USA). The samples were ionized using an ASAP probe (APCI). No chromatographic separation was done prior to the mass analysis. The calculated exact mass and spectra processing was done by Waters™ Software (Masslynx V4.1 SCN871). NMR spectra were recorded using the Bruker DPX...
400 MHz and 600 MHz Avance III HD NMR spectrometers. Chemical shifts (δ) are recorded in parts per million relative to TMS (δTMS = 0.00), CDCl₃ (δCDCl₃ = 7.26, δCDCl₃ = 77.16), or DMSO-d₆ (δH = 2.50, δC = 39.52), and coupling constants (J) are measured in hertz (Hz). Purity analyses: HPLC purity analyses were performed on an Agilent 1260 series instrument with an ACE Excel 5 C18 column (4.6 mm × 150 mm, dp = 5 µm) with a flow of 1 mL/min, UV monitoring at 320 nm, and with Agilent Chemstation as the software. Elution: 10 min linear gradient of MeCN/H₂O (35:65) to MeCN/H₂O (70:30) followed by 5 min linear gradient of MeCN/H₂O (70:30) to MeCN/H₂O (100:0). The enantiomeric excess of the intermediate 34 was controlled by HPLC using an Agilent 1100 series system detecting at 254 nM and using a Chiracel OD column (4.6 mm × 250 mm, dp = 10 µm), mobile phase: n-hexane/2-propanol, 87:13, flow rate 1.0 mL/min; tR = 8.15 min, tS = 9.47 min, Re = 1.7.

3.3. Synthetic Protocols

3.3.1. Amination of Fused Pyrimidines (General Procedure A)

The following procedure is adapted from Kaspersen et al. [45]. The pyrrolo- or thienopyrimidine (100–200 mg) was flushed with N₂ three times and dissolved in degassed n-BuOH (1–2 mL). DIPEA (0–6 equiv.) and amine (3 equiv.) were then added, and the reaction was stirred under an N₂ atmosphere at an oil bath temperature of 140 °C for 18–24 h. The solution was then cooled to an ambient temperature and the solvent was removed in vacuo, facilitated by the addition of toluene. The resulting solid was suspended with CH₂Cl₂ (3 × 25 mL) and the combined organic layers were washed with brine (25 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The material was then purified by flash chromatography as described for each specific compound.

3.3.2. Regioselective Suzuki Cross-Coupling (General Procedure B)

To a mixture of (R) or (S)-N-(1-(4-bromophenyl)ethyl)-6-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo [2,3-d] pyrimidin-4-amine (34) (100–300 mg), arylboronic acid 250 mm, dp = 5 mm), filtered, and concentrated in vacuo. The material was then purified by flash chromatography as described for each specific compound.

3.3.3. SEM-Deprotection (General Procedure C)

The following two-step procedure is adapted from Reiersølmoen et al. [46]. The SEM-protected pyrrolopyrimidine (50–100 mg) was flushed with N₂ three times and dissolved CH₂Cl₂ and TFA (1–2 mL). The reaction was then stirred under an N₂ atmosphere at ambient temperature for 3–4 h. The TFA was then removed in vacuo, and co-evaporated twice with MeOH (3 × 10 mL) to remove traces of TFA. The reaction mixture was then dissolved in 1,4-dioxane (5–10 mL) and sat. NaHCO₃ solution was added. This suspension was stirred overnight, before the solvent was removed in vacuo. The solid was then distributed between EtOAc (10–20 mL) and H₂O (10–20 mL) and separated. The aqueous layer was extracted with EtOAc (4 × 10–20 mL) and the combined organic layers were washed with brine (10–20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The solid was then purified as described in the specific experimental section.

3.4. Preparation of Compounds 1–21

3.4.1. (R)-4-(4-((1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (1)

Compound 1 was prepared as described in General Procedure C, starting from 25 (43 mg, 92.7 µmol). Immobilization on celite and purification by gradient flash chromato-
raphy (C18 silica, MeCN/H₂O, 1:9 to 3:2) resulted in 23 mg (70.8 µmol, 76%) of the desired product as a white solid, mp. 226.6–228.4 °C (decomp.), [α]£D = −290 (c 0.50, EtOH), HPLC purity: 99%, tR = 5.61 min; TLC (H₂O/MeCN:3:2) Rf = 0.30; 1H NMR (600 MHz, DMSO-d6) δ: 11.82 (s, 1H), 9.61 (s, 1H), 8.02 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.63–7.57 (m, 2H), 7.45–7.40 (m, 2H), 7.33–7.27 (m, 2H), 7.22–7.16 (m, 1H), 6.88 (d, J = 2.2 Hz, 1H), 6.85–6.80 (m, 2H), 5.49 (p, J = 7.1 Hz, 1H), 1.53 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, DMSO-d6) δ: 157.0, 154.7, 151.1, 145.6, 134.0, 128.1 (2C), 126.4, 126.05 (2C), 126.03 (2C), 123.0, 115.7 (2C), 103.9, 93.9, 48.7, 22.9; IR (neat, cm⁻¹): 3114 (O-H), 1596 (N-H), 1497 (Ar-C-H), 699 (Ar-C-H); HRMS (TOF ES⁺, m/z): calcd. for C20H15N4O [M + H]⁺: 331.1559, found: 331.1565. This material was first reported by Traxler et al. [47].

3.4.2. (R)-4-((1-((p-Tolyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (2)

Compound 2 was prepared as described in General Procedure C, starting from 26 (102 mg, 0.215 mmol). The crude material was purified by preparative LC (Agilent Prep C18 150 × 21.2 mm, 5 µm column, 20 mL/min flow, MeCN/H₂O, 30:70 to 70:30 (0–10 min linear gradient), followed by 70:30–100:0 (10–15 min linear gradient), 100 µL injection, λ = 320 nm, tR = 8.139 min), resulting in 14 mg (40.4 µmol, 19%) of the desired product as a white solid, [α]£D = −266 (c 0.50, EtOH), HPLC purity: 96%, tR = 6.49 min. 1H NMR (600 MHz, DMSO-d6) δ: 11.80 (s, 1H), 9.60 (s, 1H), 8.01 (s, 1H), 7.62 (d, J = 8.3 Hz, 1H), 7.61–7.56 (m, 2H), 7.33–7.26 (m, 2H), 7.10 (m, 2H), 6.87 (d, J = 2.2 Hz, 1H), 6.85–6.79 (m, 2H), 5.44 (p, J = 7.2 Hz, 1H), 2.25 (s, 3H), 1.50 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, DMSO-d6) δ: 156.9, 154.3, 151.1, 142.6, 135.3, 134.0, 128.7 (2C), 126.02 (2C), 125.97 (2C), 123.0, 115.7 (2C), 103.7, 94.6, 48.4, 22.9, 20.6; IR (neat, cm⁻¹): 3136 (O-H), 1598 (N-H), 1498 (Ar-C-H), 835 (Ar-C-H); HRMS (TOF ES⁺, m/z): calcd. for C21H21N4O [M + H]⁺: 345.1715, found: 345.1719.

3.4.3. (R)-4-((1-(4-Chlorophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (4)

Compound 4 was prepared as described in General Procedure C, starting from 27 (51 mg, 0.103 mmol). Extraction with EtOAc and H₂O resulted in 37 mg (0.101 mmol, 98%) of the desired product as a light-yellow solid, mp. 216.6 °C (decomp.), [α]£D = −352 (c 0.50, EtOH), HPLC purity: 96%, tR = 7.81 min. 1H NMR (600 MHz, DMSO-d6) δ: 11.84 (s, 1H), 9.62 (s, 1H), 8.01 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.63–7.58 (m, 2H), 7.46–7.41 (m, 2H), 7.38–7.33 (m, 2H), 6.87 (d, J = 2.2 Hz, 1H), 6.86–6.80 (m, 2H), 5.45 (p, J = 7.2 Hz, 1H), 1.51 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, DMSO-d6) δ: 157.0, 151.1, 144.8, 134.2, 130.9, 128.1 (2C), 128.0 (2C), 126.1 (2C), 122.9, 115.7 (2C), 103.9, 93.9, 48.2, 22.8; IR (neat, cm⁻¹): 3129 (O-H), 1599 (N-H), 1495 (Ar-C-H), 833 (Ar-C-H); HRMS (TOF ES⁺, m/z): calcd. for C21H18N4OCl [M+H]⁺ 365.1169, found: 365.1169.

3.4.4. (R)-4-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (5)

Compound 5 was prepared as described in General Procedure C, starting from 28 (42 mg, 0.078 mmol). The crude product was dissolved in MeOH (3 mL) and purified by gradient flash chromatography (C18 silica, MeOH/H₂O, 1:1 to 9:1). TLC (MeOH/H₂O, 9:1) Rf = 0.48. This afforded 22 mg (0.054 mmol, 69%) as a white solid; HPLC purity: 96%, tR = 7.37 min; [α]£D = −352.0 (1.00, EtOH (96%)); 1H NMR (600 MHz, DMSO-d6) δ: 11.81 (s, 1H), 8.00 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.59–7.57 (m, 2H), 7.51–7.48 (m, 2H), 7.39–7.38 (m, 2H), 6.84 (s, 1H), 6.81–6.79 (m, 2H), 5.43 (p, J = 7.2 Hz, 1H), 1.51 (d, J = 7.0 Hz, 3H), OH-signal not seen; 13C NMR (150 MHz, DMSO-d6) δ: 158.2, 154.5, 151.2, 150.9, 145.3, 134.5, 131.0 (2C), 128.3 (2C), 126.0 (2C), 122.0, 119.3, 116.0 (2C), 103.9, 93.5, 48.3, 22.8; IR (neat, cm⁻¹): 3328 (N-H), 3122 (O-H), 1596 (N-H), 834 (Ar-C-H); HRMS (ASAP-TOF, m/z): calcd. for C20H18N4O3Br, 409.0664 [M + H]⁺, found 409.0670.
3.4.5. (R)-4-(4-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (5) from 35

The following procedure is adapted from Kaspersen et al. [45]. Compound 35 (38 mg, 69.4 µmol) was dissolved in CH₂Cl₂ (1 mL) and stirred at 0 °C under an N₂ atmosphere. BBr₃ (1 M, 700 µL) was added dropwise over 1 hour, and the reaction was stirred for a further 1.5 h at 22 °C. The reaction was then cooled to 0 °C and quenched by the addition of H₂O (4 mL) and saturated NaHCO₃ solution (1 mL). The pH was adjusted to 4 with HCl (2 M) and saturated NaHCO₃ solution. The solution was then distributed between EtOAc (25 mL) and H₂O (25 mL) and separated. The aqueous phase was extracted with EtOAc (3 × 25 mL) and the combined organic layers were washed with brine (25 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The resulting crude product was dissolved in 1,4-dioxane (10 mL) and EtOAc (25 mL) and separated. The phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The resulting crude was immobilized on Celite and purified by gradient flash chromatography (C18 silica, MeCN/H₂O 3:2) to yield 12 mg (2.86 µmol, 56%) of the desired product as a light-yellow solid, mp. 254.9-256.0 °C. The combined organic phases were washed with brine (25 mL) and separated. The aqueous phase was washed with brine (25 mL) and EtOAc (25 mL). The pH in the aqueous phase was adjusted to 5 with HCl (2 M) and saturated NaHCO₃ solution. The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The resulting crude was purified by flash chromatography (silica, EtOAc/n-hexane 0:1 to 1:1) to yield 49 mg (0.199 mmol, 63%) of the desired product as a light-yellow solid. The 1H NMR spectroscopic data confirmed with that which is reported above [45].

3.4.6. (R)-4-(4-((1-(4-Iodophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (6)

Compound 6 was prepared as described in General Procedure C, starting from 29 (51 mg, 86.1 µmol). Immobilization on celite and purification by gradient flash chromatography (C18 silica, MeCN/H₂O 1:9 to 3:2) resulted in 22 mg (48.4 µmol, 56%) of the desired product as a light-yellow solid, mp. 254.9-256.0 °C (decomp.), TLC (MeCN/H₂O 3:2) Rf = 0.24; [α]D²⁰ = -236 (c 0.50, EtOH), HPLC purity: 97%, tR = 7.85 min. 1H NMR (600 MHz, DMSO-d₆) δ: 11.84 (s, 1H), 9.62 (s, 1H), 8.00 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.68–7.63 (m, 2H), 7.63–7.57 (m, 2H), 7.26–7.21 (m, 2H), 6.86 (d, J = 2.1 Hz, 1H), 6.85–6.76 (m, 2H), 5.40 (p, J = 7.2 Hz, 1H), 1.50 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, DMSO-d₆) δ: 157.0, 151.3, 151.1, 145.7, 136.9 (2C), 134.2, 128.5 (2C), 126.1 (2C), 122.9, 115.7 (2C), 103.9, 93.9, 92.0, 48.4, 22.7; IR (neat, cm⁻¹): 3139 (O-H), 1598 (N-H), 1498 (Ar C-H), 834 (Ar C-H); HRMS (TOF ES⁺, m/z): calcd. for C₂₀H₁₈N₄O [M + H⁺]: 347.1265, found: 347.1263.

3.4.7. (R)-4-(4-((1-(3-Bromophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (7)

Compound 7 was prepared as described in General Procedure C, starting from 30 (103 mg, 0.190 mmol). Immobilization on celite and purification by gradient flash chromatography (silica, EtOAc/n-pentane 0:1 to 1:1) resulted in 49 mg (0.199 mmol, 63%) of the desired product as an off-white solid, decomp. at 237.5–240.1 °C, TLC (EtOAc/n-pentane 1:1) Rf = 0.39; [α]D²⁰ = -228 (c 0.5, EtOH), HPLC purity: 98%, tR = 7.24 min. 1H NMR (600 MHz, DMSO-d₆) δ: 11.86 (s, 1H), 9.62 (s, 1H), 8.02 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.64–7.58 (m, 3H), 7.45–7.40 (m, 1H), 7.40–7.37 (m, 1H), 7.27 (t, J = 7.8 Hz, 1H), 6.86 (d, J = 2.2 Hz, 1H), 6.86–6.80 (m, 2H), 5.48–5.43 (m, 1H), 1.51 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, DMSO-d₆) δ: 157.0, 154.5, 151.1, 148.8, 134.3, 130.5, 129.3, 128.7, 126.1, 125.3, 122.9, 121.6, 115.7, 103.9, 93.8, 48.4, 22.9; IR (neat, cm⁻¹): 3111 (O-H), 1598 (N-H), 1498 (Ar C-H), 834 (Ar C-H); HRMS (TOF ES⁺, m/z): calcd. for C₂₀H₁₈N₄O³⁵Br [M + Br⁺]: 409.0688, found: 409.0667.

3.4.8. 4-((4-Bromobenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (8)

Compound 8 was prepared as described in General Procedure C starting from 31 (111 mg, 0.211 mmol). Immobilization on celite and purification by gradient flash chromatography (C18 silica, MeCN/H₂O 1:9 to 1:1) gave the desired product in a yield of 11 mg (28.5 µmol, 13%) as an off-white solid, TLC (MeCN/H₂O 3:2) Rf = 0.33; HPLC purity:
3.4.9. (S)-4-(4-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (9)

Compound 9 was prepared as described in General Procedure C starting from 33 (98.8 mg, 0.183 mmol). Immobilization on celite and purification by gradient flash chromatography (C18 silica, MeCN/H2O, 1:9 to 1:0). This gave 49 mg (48.7 mg, 0.199 mmol, 65%) of a white solid, mp. 253.1–254.5 °C (decomp.); TLC (MeOH/H2O, 9:1) \( R_f = 0.48; ^1H \) NMR (600 MHz, DMSO-d6): \( \delta = 11.85 \) (s, 1H), 9.63 (s, 1H), 8.02 (s, 1H), 7.72 (d, \( J = 8.0 \) Hz, 1H), 7.61 (d, \( J = 8.1 \) Hz, 2H), 7.49 (d, \( J = 8.5 \) Hz, 2H), 7.38 (d, \( J = 8.5 \) Hz, 2H), 6.87 (s, 1H), 6.84 (d, \( J = 8.0 \) Hz, 2H), 5.43 (p, \( J = 7.2 \) Hz, 1H), 1.51 (d, \( J = 7.0 \) Hz, 3H); \(^1^3\)C NMR (151 MHz, DMSO-d6): \( \delta = 157.0, 154.6, 151.3, 145.2, 134.2, 131.0 (2C), 128.4 (2C), 126.3 (2C), 122.6, 120.0, 115.6 (2C), 103.6, 96.8, 51.9, 40.1, 31.5, 16.2; IR (neat, cm\(^{-1}\)): 2975 (C-H), 1547 (N-H), 834 (Ar-C-H), 548 (C-Br); HRMS (TOF ES+; m/z): calcd. for C\(_{29}\)H\(_{28}\)N\(_4\)O\(_7\)Br [M + H]^+ 409.0664, found: 409.0664. The \(^1H\) NMR shifts are found at higher field than that reported for the corresponding HBr-salt [48].

3.4.10. (R)-4-(4-((1-(4-Bromophenyl)ethyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol (10)

Compound 10 was prepared as described in General Procedure C starting from 33 (52 mg, 93.9 \( \mu \)mol). Immobilization on celite and purification by gradient flash chromatography (silica, MeOH/CH\(_2\)Cl\(_2\); 0:100 to 5:95) yielded a yellow solid, which after a wash with toluene (5 mL) resulted in the desired product with a yield of 59% (18.8 mg, 44.5 mmol) as an off-white solid, TLC (MeOH/CH\(_2\)Cl\(_2\); 3:2) \( R_f = 0.24; \left[\alpha\right]_{D}^{20} = -10.0 \) (c 0.50, DMF); HPLC purity: 98.5%, \( t_R = 9.57 \) min; \(^1H\) NMR (600 MHz, DMSO-d6): \( \delta = 12.00 \) (s, 1H), 9.58 (s, 1H), 8.13 (s, 1H), 7.72–7.65 (m, 2H), 7.58–7.49 (m, 2H), 7.32–7.24 (m, 2H), 6.88 (d, \( J = 2.2 \) Hz, 1H), 6.84–6.76 (m, 2H), 6.39 (s, 1H), 3.06 (s, 3H), 1.58 (d, \( J = 7.0 \) Hz, 3H); \(^1^3\)C NMR (151 MHz, DMSO-d6): \( \delta = 157.0, 156.2, 152.8, 150.5, 141.3, 133.9, 131.3 (2C), 129.2 (2C), 126.3 (2C), 122.6, 120.0, 115.6 (2C), 103.6, 96.8, 51.9, 40.1, 31.5, 16.2; IR (neat, cm\(^{-1}\)): 3115 (O-H), 1568 (N-H), 1490 (Ar-C-H), 827 (Ar-C-H); HRMS (TOF ES+; m/z): calcd. for C\(_{31}\)H\(_{29}\)N\(_4\)O\(_7\)Br [M + H]^+ + 423.0820, found: 423.0826.

3.4.11. (S)-N-(1-(4-Bromophenyl)ethyl)-6-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (11)

Compound 11 was prepared as described in General Procedure C starting from 35 (120 mg, 0.217 mmol). The crude product was purified twice by C18 silica flash chromatography (first MeOH/EtOAc, 3:1, then: acetone/H\(_2\)O, 1:1; TLC (C18 silica acetone/H\(_2\)O, 1:1) \( R_f = 0.68 \). This gave 33 mg (0.078 mmol, 36%) as an off-white solid; HPLC purity: 98%, \( t_R = 9.86 \) min; \( \left[\alpha\right]_{D}^{20} = +288.2 \) (1.00, EtOH (100%)); \(^1H\) NMR (600 MHz, DMSO-d6): \( \delta = 11.932–11.929 \) (m, 1H), 8.02 (s, 1H), 7.76 (d, 1H, \( J = 8.1 \) Hz), 7.73–7.71 (m, 2H), 7.50–7.48 (m, 2H), 7.39–7.37 (m, 2H), 7.03–7.01 (m, 2H), 6.94–6.93 (br d, 1H, \( J = 1.6 \) Hz), 5.43 (quint, 1H, \( J = 7.2 \) Hz), 3.80 (br s, 3H), 1.51 (d, 3H, \( J = 7.0 \) Hz); \(^1H\) NMR is in accordance with that reported at 400 MHz [48].

3.4.12. (R)-N-(1-(4-Bromophenyl)ethyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (12)

Compound 12 was prepared as described in General Procedure C starting from 36 (63 mg, 0.120 mmol). The crude product was purified twice by C18 silica gradient flash chromatography (first: acetone/MeOH, 0:100 to 1:4 acetone/MeOH, then: MeOH/H\(_2\)O, 1:1 to 9:1. TLC (C-18 silica, acetone/MeOH, 1:4) \( R_f = 0.50 \). This gave 32 mg (0.082 mmol, 68%)
as a white solid; HPLC purity >99% tR = 10.03 min; [α]D20 = −369.0 (1.00, EtOH abs); 1H NMR (600 MHz, DMSO-d6) δ: 12.05 (s, 1H), 8.05 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.80–7.78 (m, 2H), 7.51–7.48 (m, 2H), 7.46–7.43 (m, 2H), 7.39–7.37 (m, 2H), 7.31–7.28 (m, 1H), 7.09 (d, J = 1.6 Hz, 1H), 5.44 (quint., J = 7.4 Hz, 1H), 1.52 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, DMSO-d6) δ: 154.9, 151.7, 151.6, 145.1, 133.5, 131.7, 131.0 (2C), 129.0 (2C), 128.3 (2C), 127.3, 124.5 (2C), 119.4, 103.9, 96.0, 48.3, 22.7; IR (neat, cm−1): 3415 (N-H), 3114 (C-H), 1595 (N-H), 1475 (Ar C-H), 751 (C-H); HRMS (ASAP-TOF, m/z): calcd. for C20H18N4O7Br, 393.0715 [M + H]+, found 393.0715.

3.4.13. (R)-N-(1-(4-Bromophenyl)ethyl)-6-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (13)

Compound 13 was prepared as described in General Procedure C starting from 37 (63 mg, 0.116 mmol). The crude product was purified by gradient flash chromatography (C18 silica, MeOH/H2O, 1:1 to 9:1). TLC (MeOH/H2O, 9:1, RF = 0.20). This gave 37 mg (0.090 mmol, 78%) as a white solid; HPLC purity: 99%, tR = 10.30 min; [α]D20 = −317.0 (1.00, EtOH abs). 1H NMR (600 MHz, CDCl3) δ: 12.82 (s, 1H), 8.31 (s, 1H), 7.75–7.69 (m, 2H), 7.50–7.45 (m, 2H), 7.35–7.30 (m, 2H), 7.21–7.14 (m, 2H), 6.53 (d, J = 1.9 Hz, 1H), 5.52 (p, J = 7.0 Hz, 1H), 5.28 (s, 1H), 1.66 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ: 162.7 (d, J = 247.6 Hz), 155.5, 152.0, 151.6, 143.3, 135.3, 131.9 (2C), 128.5 (d, J = 3.2 Hz), 128.0 (2C), 127.3 (d, J = 8.8 Hz, 2C), 121.2, 116.3 (d, J = 22.0 Hz, 2C), 104.6, 94.5, 49.9, 23.0; 19F NMR (376 MHz, CDCl3, C6D6) δ: −116.3 (s); IR (neat, cm−1): 3428 (N-H), 2976 (C-H), 1596 (N-H), 1496 (Ar C-H), 834 (Ar C-H); HRMS (ASAP-TOF, m/z): calcd. for C20H17N4BrF279, 411.0621 [M + H]+, found 411.0621.

3.4.14. (R)-N-(1-(4-Bromophenyl)ethyl)-6-(4-nitrophenyl)-7H-pyrrolo [2,3-d]pyrimidin-4-amine (14)

Compound 14 was prepared as described in General Procedure C starting from 38 (185 mg, 0.325 mmol). The crude product was dissolved in DMF (2 mL) at 75 °C and water was added dropwise until saturation, which produced precipitation upon cooling. This afforded 73 mg (0.167 mmol, 51%) of a yellow-orange solid; HPLC purity: 96%, tR = 10.37 min; [α]D20 = −635.0 (1.00, DMSO); 1H NMR (600 MHz, DMSO-d6) δ: 12.37 (s, 1H), 8.32–8.30 (m, 2H), 8.11 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 8.03–8.00 (m, 2H), 7.51–7.49 (m, 2H), 7.39–7.37 (m, 3H), 5.45 (p, J = 7.1 Hz, 1H), 1.53 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, DMSO-d6) δ: 155.3, 153.0, 152.3, 145.7, 144.8, 138.0, 131.2, 131.1 (2C), 128.3 (2C), 125.0 (2C), 124.5 (2C), 119.5, 104.2, 100.1, 48.4, 48.2, 22.6; IR (neat, cm−1): 3407 (N-H), 2973 (C-H), 1601 (N-H), 1536 (N-O), 1489 (Ar C-H), 828 (Ar C-H); HRMS (ASAP-TOF, m/z): calcd. for C20H17N4O279Br, 438.0566 [M + H]+, found 438.0563.

3.4.15. (R)-6-(4-Aminophenyl)-N-(1-(4-bromophenyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (15)

To a mixture the nitro derivative 14 (40 mg, 0.091 mmol), NH4Cl (44 mg, 0.823 mmol) and Fe-powder (15 mg, 0.276 mmol) under a N2 atmosphere, water (0.9 mL), and EtOH (96%, 2.1 mL) were added. The mixture was stirred at 78 °C for 5 hours before full conversion was observed by TLC. The mixture was filtered through a celite pad, which was washed with EtOAc (75 mL) and MeOH (100 mL), and the solution was dried in vacuo. The solids were added to water (20 mL) and EtOAc (50 mL), and the aqueous layer was adjusted to pH 9 with NaHCO3 before the layers were separated, and the aqueous layer was extracted with additional EtOAc (3 × 20 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by gradient flash chromatography (C18 silica, MeOH/H2O, 1:1 to 9:1). TLC (MeOH/H2O, 9:1) Rf = 0.39. This afforded 17 mg (0.042 mmol, 45%) as an off-white solid; HPLC purity: 96%, tR = 7.34 min; [α]D20 = −315 (1.00, acetone). 1H NMR (600 MHz, DMSO-d6) δ: 11.71 (br s, 1H), 7.98 (s, 1H), 7.66 (d, J = 8.1 Hz, 1H), 7.50–7.45 (m, 4H), 7.38–7.37 (m, 2H), 6.76 (d, J = 2.1 Hz, 1H), 6.62–6.60 (m, 2H), 5.42 (p, J = 7.2 Hz, 1H), 1.50 (d, J = 7.0 Hz, 3H) (NH2-signal not observed); 13C NMR (150 MHz, DMSO-d6) δ: 154.2, 151.1, 150.5, 148.4, 145.3, 135.1, 131.0.
(2C), 128.3 (2C), 125.7 (2C), 119.4, 119.3, 114.0 (2C), 104.0, 92.5, 48.3, 22.8; IR (neat, cm\(^{-1}\)): 3342 (N-H), 3214 (N-H), 2923 (C-H), 1594 (N-H), 1476 (Ar C-H), 825 (Ar C-H); HRMS (ASAP-TOF, m/z): calcd. for C\(_{20}\)H\(_{10}\)N\(_5\)S\(_{38}\)Br, 408.0824 [M + H]\(^+\), found 408.0829.

3.4.16. Methyl (R)-4-((1-(4-bromophenyl)ethyl)amino)-7H-pyrrrolo[2,3-\(d\)]pyrimidin-6-yl)benzene-sulfonamide (16)

Compound 16 was prepared as described in General Procedure C starting from 39 (74 mg, 0.127 mmol). The crude product was suspended in acetone (3 mL) and centrifuged at 4400 rpm for 10 min before the supernatant was removed. This gave 31 mg (0.069 mmol, 54%) as a white powder; HPLC purity: 99%, \(t_R = 10.03\) min; \([\alpha]_{D}^{20} = -467.0\) (c 1.00, DMSO); \(^1\)H NMR (600 MHz, DMSO-\(d_6\)) \& 12.23 (d, \(J = 2.2\) Hz, 1H), 8.08 (s, 1H), 8.03–8.01 (m, 2H), 7.97 (d, \(J = 8.0\) Hz, 1H), 7.93–7.91 (m, 2H), 7.51–7.49 (m, 2H), 7.28 (d, \(J = 2.1\) Hz, 1H), 5.45 (p, \(J = 7.2\) Hz, 1H), 3.87 (s, 3H), 1.52 (d, \(J = 7.0\) Hz, 3H); \(^13\)C NMR (150 MHz, DMSO-\(d_6\)) \& 165.9, 155.2, 152.5, 152.0, 144.9, 136.2, 132.2, 131.1 (2C), 129.9 (2C), 128.3 (2C), 127.7, 124.4 (2C), 119.4, 104.0, 98.4, 52.1, 48.4, 22.7; IR (neat, cm\(^{-1}\)): 3369 (N-H), 2969 (C-H), 1696 (C=O), 1597 (N-H), 1475 (Ar C-H), 823 (Ar C-H), 602 (C-Br); HRMS (ASAP-TOF, m/z): calcd. for C\(_{22}\)H\(_{20}\)N\(_5\)O\(_3\)S\(_{38}\)Br, 451.0770 [M + H]\(^+\), found 451.0770.

3.4.17. (R)-4-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrrolo[2,3-\(d\)]pyrimidin-6-yl)benzene-sulfonamide (17)

Compound 17 was prepared as described in General Procedure C starting from 40 (122 mg, 0.202 mmol). The crude material was purified by gradient flash chromatography (C18 silica, acetone/H\(_2\)O, 1:0 to 1:1). TLC (acetone/H\(_2\)O, 1:1) \(R_f = 0.25\). This afforded 67 mg (0.142 mmol, 70%) as a white powder; HPLC purity: 96%, \(t_R = 6.875\) min; \([\alpha]_{D}^{20} = -367.0\) (1.00, acetone); \(^1\)H NMR (600 MHz, DMSO-\(d_6\)) \& 12.22 (d, \(J = 1.2\) Hz, 1H), 8.09 (s, 1H), 7.98 (d, \(J = 8.0\) Hz, 1H), 7.34–7.32 (m, 2H), 7.52–7.49 (m, 2H), 7.40–7.37 (m, 4H), 7.25 (d, \(J = 2.0\) Hz, 1H), 5.45 (q., \(J = 7.2\) Hz, 1H), 1.53 (d, \(J = 7.0\) Hz); \(^13\)C NMR (150 MHz, DMSO-\(d_6\)) \& 155.2, 152.4, 151.9, 145.0, 124.2, 134.8, 132.0, 131.1 (2C), 128.3 (2C), 126.4 (2C), 124.6 (2C), 119.4, 104.0, 98.2, 48.4, 22.7; IR (neat, cm\(^{-1}\)): 3376 (N-H), 2923 (C-H), 1593 (N-H), 1477 (Ar C-H), 1331 (S=O), 827 (Ar C-H), 621 (C-Br); HRMS (ASAP-TOF, m/z): calcd. for C\(_{20}\)H\(_{18}\)N\(_5\)O\(_3\)S\(_{38}\)Br, 472.0443 [M + H]\(^+\), found 472.0444.

3.4.18. (R)-2-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrrolo[2,3-\(d\)]pyrimidin-6-yl)phenol (18)

Compound 18 was prepared as described in General Procedure C starting from 41 (48 mg, 0.089 mmol). The crude product was purified by gradient flash chromatography (C18 silica, acetone/H\(_2\)O, 1.3 to 4.1). TLC (C18 silica, acetone/H\(_2\)O,4:1) \(R_f = 0.77\). This afforded 24 mg (0.059 mmol, 66%) as a white powder; HPLC purity: 97%, \(t_R = 8.43\) min; \([\alpha]_{D}^{20} = -367.0\) (1.00, EtOH); \(^1\)H NMR (600 MHz, DMSO-\(d_6\)) \& 11.58 (br s, 1H), 10.06 (br s, 1H), 8.02 (s, 1H), 7.87 (d, \(J = 8.0\) Hz, 1H), 7.71 (dd, \(J = 7.8, 1.7\) Hz, 1H), 7.50–7.47 (m, 2H), 7.39–7.37 (m, 2H), 7.28 (s, 1H), 7.11 (dd, \(J = 8.1, 7.2, 1.6\) Hz, 1H), 6.98 (dd, \(J = 8.2, 1.2\) Hz, 1H), 6.87 (td, \(J = 7.5, 1.2\) Hz, 1H), 5.45 (q., \(J = 7.2\) Hz, 1H), 1.51 (d, \(J = 7.1\) Hz, 3H); \(^13\)C NMR (150 MHz, DMSO-\(d_6\)) \& 154.8, 154.4, 151.3, 150.6, 145.3, 145.3 (10C), 145.7 (2C), 130.7, 128.4 (2C), 127.9, 126.9, 119.3 (2C)*, 118.5, 116.5, 103.7, 99.4, 48.3, 22.6, 2 overlapping signals revealed by HMBC; IR (neat, cm\(^{-1}\)): 3404 (N-H), 3046 (O-H), 2969 (C-H), 1596 (N-H), 1470 (Ar C-H), 822 (Ar C-H), 582 (C-Br); HRMS (ASAP-TOF, m/z): calcd. for C\(_{20}\)H\(_{18}\)N\(_4\)O\(_3\)Br, 409.0664 [M + H]\(^+\), found 409.0665.

3.4.19. (R)-3-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrrolo[2,3-\(d\)]pyrimidin-6-yl)phenol (19)

Compound 19 was prepared as described in General Procedure C starting from 42 (47 mg, 0.087 mmol). The crude product was purified by gradient flash chromatography (C18 silica, acetone/H\(_2\)O, 1:1 to 2:1). TLC (silica-gel, acetone/\textit{n}-pentane 1:2) \(R_f = 0.24\). This gave 2 mg (0.068, 78%) as a white solid; HPLC purity: 97%, \(t_R = 7.65\) min; \([\alpha]_{D}^{20} = -296.0\)
(c 1.00, EtOH); $^1$H NMR (600 MHz, DMSO-d$_6$) $\delta$: 11.96 (br d, $J = 2.3$ Hz, 1H), 9.54 (s, 1H), 8.04 (s, 1H), 7.82 (d, $J = 8.0$ Hz, 1H), 7.50–7.48 (m, 2H), 7.39–7.37 (m, 2H), 7.23–7.21 (m, 2H), 7.164–7.157 (m, 1H), 7.00 (br d, $J = 2.2$ Hz 1H), 6.72–6.70 (m, 1H), 5.44 (quint., $J = 7.2$ Hz, 1H), 1.52 (d, $J = 7.0$ Hz, 3H); $^{13}$C NMR (150 MHz, DMSO-d$_6$) $\delta$: 157.7, 154.9, 151.6, 151.4, 145.1, 133.7, 133.0, 131.0 (2C), 129.9, 128.3 (2C), 119.3, 115.5, 114.5, 111.5, 95.9, 48.3, 30.7, 22.7; IR (neat, cm$^{-1}$): 3119 (O-H), 2973 (C-H), 1586 (N-H), 1495 (Ar C-H), 825 (Ar C-H); HRMS (TOF, m/z): calcd. for C$_2$H$_{18}$N$_4$O$_7$Br, 409.0664 [M + H]$^+$, found 409.0670.

3.4.20. (R)-N-(1-(4-bromophenyl)ethyl)-6-(4-methoxyphenyl)thieno [2,3-d]pyrimidin-4-amine (20)

4-Chloro-6-(4-methoxyphenyl)thieno [2,3-d] pyrimidine (44) (228 mg, 0.823 mmol) and (R)-1-(4-bromophenyl)ethan-1-amine (365 µL, 2.50 mmol) were reacted as described in General Procedure A. The resulting crude material was purified by gradient flash chromatography (silica, EtOAc/n-pentane, 0:1 to 1:1), resulting in 187 mg (0.424 mmol, 52%) of the desired product as a yellow solid, mp. 107.1–109.4 °C, TLC (EtOAc/n-pentane 4:1) $R_f = 0.29$; $[\alpha]_{D}^{20} = −416$ (c 0.50, EtOH), HPLC purity >99%, $t_k = 13.93$ min. $^1$H NMR (600 MHz, DMSO-d$_6$) $\delta$: 8.25 (s, 1H), 8.18 (d, $J = 7.7$ Hz, 1H), 8.02 (s, 1H), 7.66–7.60 (m, 60%), 7.54–7.48 (m, 2H), 7.41–7.35 (m, 2H), 7.11–7.05 (m, 2H), 5.45 (t, $J = 7.2$ Hz, 1H), 3.82 (s, 3H), 1.55 (d, $J = 7.0$ Hz, 3H); $^{13}$C NMR (151 MHz, DMSO-d$_6$) $\delta$: 164.7, 159.6, 155.5, 153.5, 144.2, 138.4, 131.2 (2C), 128.3 (2C), 127.0 (2C), 125.8, 119.6, 117.6, 114.8 (2C), 113.8, 55.3, 48.7, 22.4; IR (neat, cm$^{-1}$): 3297 (N-H), 1607 (N-H), 1523 (Ar C-H), 825 (Ar C-H); HRMS (TOF ES+, m/z): calcd. for C$_{21}$H$_{19}$BrN$_3$O$_8$ [M + H]$^+$: 440.0432, found: 440.0436.

3.4.21. (R)-4-((1-(4-Bromophenyl)ethyl)amino)thieno[2,3-d]pyrimidin-6-yl)phenol (21)

(R)-N-(1-(4-bromophenyl)ethyl)-6-(4-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine (100 mg, 0.228 mmol) was flushed three times with N$_2$ and dissolved in dry CH$_2$Cl$_2$ (2 mL). The reaction was cooled to 0 °C and BBr$_3$ in DCM (1 M, 2.5 mL) was added dropwise over 1 h. After a further 3.5 h, the reaction was quenched with H$_2$O (7.5 mL) and sat. NaHCO$_3$ solution (5 mL). EtOAc (10 mL) was then added, and the phases separated. The aqueous layer was extracted with EtOAc (5 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuo. The resulting crude material was immobilized on celite and purified by gradient flash chromatography (C18 silica, MeCN/H$_2$O, 1:9 to 2:3), resulting in 58 mg (0.137 mmol, 60%) of the desired product as a yellow solid, mp. 144.1–145.4 °C, TLC (MeCN/H$_2$O 2:1) $R_f = 0.19$; $[\alpha]_{D}^{20} = −434$ (c 0.50, EtOH), HPLC purity >98%, $t_k = 10.69$ min; $^1$H NMR (600 MHz, DMSO-d$_6$) $\delta$: 9.84 (s, 1H), 8.23 (s, 1H), 8.15 (d, $J = 7.7$ Hz, 1H), 7.95 (s, 1H), 7.59–7.47 (m, 4H), 7.44–7.32 (m, 2H), 6.96–6.85 (m, 2H), 5.44 (p, $J = 7.1$ Hz, 1H), 1.54 (d, $J = 7.0$ Hz, 3H); $^{13}$C NMR (151 MHz, DMSO-d$_6$) $\delta$: 164.5, 158.1, 155.4, 153.3, 144.3, 139.0, 131.2 (2C), 128.3 (2C), 127.2 (2C), 124.2, 119.6, 117.6, 116.1 (2C), 113.1, 48.7, 40.1, 39.9, 22.4; IR (neat, cm$^{-1}$): 3321 (O-H), 2973 (Ar C-H), 1586 (N-H), 1545 (Ar C-H), 825 (Ar C-H); HRMS (TOF ES+, m/z): calcd. for C$_{20}$H$_{17}$BrN$_3$O$_8$ [M + H]$^+$: 426.0276, found: 426.0283.

3.5. Bioassays

3.5.1. MIC Measurements

The MIC of compound 1–21 towards *Escherichia coli* (MG1655) and *Staphylococcus aureus* (ATCC29213) was determined following the standards that were recommended by the Clinical and Laboratory Standards Institute (CLSI) for the broth microdilution method [40]. Briefly, the bacterial suspensions were adjusted to 0.5 McFarland standard (−1 × 10$^8$ colony forming units (CFU)/mL) and diluted 1:200 in Cation-Adjusted Mueller-Hinton Broth (CAMHB, 22.5 mg/mL Ca$^{2+}$, 11 mg/mL Mg$^{2+}$). The suspension was subsequently added to polypropylene microtiter plates (100 µL/well, −5 × 10$^4$ CFU/well) that were already prepared with different concentrations of the various halogenated fused pyrimidines (11 µL/well, two-fold serial dilutions). The plates were incubated at 37 °C overnight before inspection for visible growth and determination of the MIC values.
3.5.2. E. coli and Human TMPK Assay

The inhibition of EcTMPK was determined by Profoldin using the E. coli Thymidylate Kinase Assay Kit Plus (ProFoldin, Catalog No. TMK100KE, Hudson, MA, USA), where dTMP was phosphorylated by ATP that was catalyzed by TMPK. The assay was run in 96-well black plates at 36 °C. The formation of ADP was measured by adding a fluorescent dye and measuring the fluorescence emission at 535 nm after excitation at 485 nm. The readout was corrected for emission from the assay cocktail and DMSO. An ADP control assay was also performed to correct for possible interference with ADP detection. Single-point inhibitions were measured at 8.3 µM inhibitor concentrations. The IC₅₀-values were determined from a similar assay, where 2-fold dilution series from 200 mM to 0.391 mM were used. The assay towards the human enzyme was run similarly but using the Human Thymidylate Kinase Assay Kit Plus-500 (Catalog Number: HTMK500KE, ProFoldin, Hudson, MA, USA).

3.5.3. In Vitro EGFR (ErbB1) Inhibitory Potency

The compounds were supplied in a 10 mM DMSO solution, and enzymatic EGFR (ErbB1) inhibition potency was determined by Invitrogen (ThermoFisher) using their Z’-LYTE® assay technology. [49] The compounds were tested for their inhibitory activity at 100 nM in duplicates. The IC₅₀ values that were reported for 1 and 5 are based on the average of 2 titration curves (20 data points), and were calculated from activity data with a four-parameter logistic model using SigmaPlot (Windows Version 12.0 from Systat Software, Inc., Palo Alto, CA, USA). Unless stated otherwise, the ATP concentration that was used was equal to apparent K_m.

3.5.4. Kinase Panel

The compounds were supplied in a 10 mM DMSO solution, and enzymatic kinase inhibition potency was determined by ThermoFisher (Invitrogen, Waltham, MA, USA) using their Z’-LYTE® assay technology [49], at 500 nM in duplicates. The ATP concentration that was used was equal to K_m, except when this service was not provided, and other concentrations had to be used.

4. Conclusions

A total of 21 different fused pyrimidines were synthesized and investigated for their antibacterial activity towards E. coli and S. aureus. The SAR study identified two highly active pyrrolopyrimidines with low MIC values towards S. aureus, while none were effective against E. coli. Moreover, the SAR study showed that only a minor alteration in the structure affected the activity profoundly, which indicates that the compounds act on a specific intracellular target rather than on the cellular membrane. A hydroxyl group on the meta- or para position of the 6-aryl unit was found crucial for activity, and heavy halogens (bromo and iodo) in the 4-benzylamine group was strongly potency inducing. Interestingly, when the most potent derivatives were evaluated in combination with the antimicrobial peptide betatide, a four-fold decrease in the MIC value was obtained, a strategy which might be promising for avoiding resistance. The detailed mode of action is currently not known. However, the front runner compound was shown to be a moderately active inhibitor towards E. coli TMPK in enzymatic assays and this is also a possible target in S. aureus. No major interferences with human kinases were found.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/antibiotics11080984/s1, Supporting Files: Synthesis of building blocks, NMR spectroscopy and Comparison of TMPK folding. References [12,46,50–53] are cited in the supplementary materials.

Author Contributions: Conceptualization, B.H.H.; synthesis, C.E.O. and F.H.B.; biological studies, C.K.S., L.M.R., A.H.S. and O.E.T.B.; writing—original draft preparation, C.E.O. and B.H.H.; writing—review and editing, C.E.O. and B.H.H.; visualization, E.S.; supervision, P.B., M.O., E.S. and
References

1. Nuding, S.; Frasch, T.; Schaller, M.; Stange, E.; Zabel, L. Synergistic Effects of Antimicrobial Peptides and Antibiotics against Clostridium difficile. Antimicrob. Agents Chemother. 2014, 58, 5719-5725. [CrossRef]

2. Rajasekaran, G.; Kim, E.Y.; Shin, S.Y. LL-37-derived membrane-active FK-13 analogs possessing cell selectivity, anti-biofilm activity and synergy with chloramphenicol and anti-inflammatory activity. Biochim. Biophys. Acta. 2017, 1859, 722–733. [CrossRef]

3. Naghmouchi, K.; Le Lay, C.; Baah, J.; Drider, D. Antibiotic and antimicrobial peptide combinations: Synergistic inhibition of Pseudomonas fluorescens and antibiotic-resistant variants. Res. Microbiol. 2012, 163, 101–108. [CrossRef]

4. Kampshoff, F.; Willcox, M.D.P.; Dutta, D. A Pilot Study of the Synergy between Two Antimicrobial Peptides and Two Common Antibiotics. Antibiotics 2019, 8, 60. [CrossRef]

5. Ruden, S.; Rieder, A.; Chis Ster, I.; Schwartz, T.; Mikut, R.; Hilpert, K. Synergy Pattern of Short Cationic Antimicrobial Peptides Against Multidrug-Resistant Pseudomonas aeruginosa. Front. Microbiol. 2019, 10, 2740. [CrossRef]

6. Rodriguez-Rojas, A.; Nath, A.; El Shazely, B.; Santi, G.; Kim, J.J.; Weise, C.; Kuroppka, B.; Rolff, J. Antimicrobial Peptide Induced-Stress Renders Staphylococcus aureus Susceptible to Toxic Nucleoside Analogs. Front. Immunol. 2020, 11, 1686. [CrossRef]

7. Zheng, X.; Cao, Q.; Cao, Q.; Mao, F.; Li, X.; Zhu, J.; Lan, L.; Li, J. Discovery of synergistic activity of fluoroquinolones in combination with antimicrobial peptides against clinical polymyxin-resistant Pseudomonas aeruginosa DK2. Chin. Chem. Lett. 2020, 31, 413–417. [CrossRef]

8. Duong, L.; Gross, S.P.; Siryaporn, A. Developing Antimicrobial Synergy With AMPs. Front. Med. Technol. 2021, 3, 640981. [CrossRef]

9. Nedal, A.; Raeder, S.B.; Dalhus, B.; Helgesen, E.; Forström, R.J.; Lindland, K.; Søgaard, C.K.; Haugan, M.S.; Otterlei, M. Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Front. Microbiol. 2021, 12, 76451. [CrossRef]

10. Hopestra, R.; Dumez, H.; Eskens, F.A.; van der Gaast, A.; de Heus, G.; Sizer, K.C.; Ravera, C.; Vaidyanathan, S.; Bucana, C.; et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 2005, 11, 6908–6915. [CrossRef]

11. Blindheim, F.H.; Malme, A.T.; Dalhus, B.; Sundby, E.; Hoff, B.H. Synthesis and Evaluation of Fused Pyrimidines as E. coli Thymidylate Monophosphate Kinase Inhibitors. ChemistrySelect 2021, 6, 12852–12857. [CrossRef]

12. Mesa, R.A.; Yasothon, U.; Kirkpatrick, P. Ruxolitinib. Nat. Rev. Drug Discov. 2012, 11, 103–104. [CrossRef]

13. Tian, F.; Chen, Z.; Xu, T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: A systematic review and meta-analysis. J. Int. Med. Res. 2019, 47, 2342–2350. [CrossRef]

14. De Coen, L.M.; Heugebaert, T.S.A.; Garcia, D.; Stevens, C.V. Synthetic Entries to and Biological Activity of Pyrrolopyrimidines. Chem. Rev. 2016, 116, 80–139. [CrossRef]

15. Adel, M.; Serya, R.A.T.; Lasheen, D.S.; Abouzid, K.A.M. Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy. Drug Res. 2018, 68, 485–498. [CrossRef]

16. Liu, Y.; Gong, R.; Liu, X.; Zhang, P.; Zhang, Q.; Cai, Y.-S.; Deng, Z.; Winkler, M.; Wu, J.; Chen, W. Discovery and characterization of the tuberculid biosynthetic pathway from Streptomyces tuberculicus NBRC 13090. Microb. Cell Factories 2018, 17, 131. [CrossRef]

17. Mohamed, M.S.; El-Domany, R.A.; Abd El-Hameed, R.H. Synthesis of certain pyrrole derivatives as antimicrobial agents. Acta Pharm. 2009, 59, 145–158. [CrossRef]

18. Tak, L.W.; Trzoss, M.; Bensen, D.C.; Li, X.; Chen, Z.; Lam, T.; Zhang, J.; Creighton, C.J.; Cunningham, M.L.; Kwan, B.; et al. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and
optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. *Bioorg. Med. Chem. Lett.* 2013, 23, 1529–1536. [CrossRef]

20. Trzoss, M.; Benson, D.C.; Li, X.; Chen, Z.; Lam, T.; Zhang, J.; Creighton, C.J.; Cunningham, M.L.; Kwan, B.; Stidham, M.; et al. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum activity. Gram-negative antibacterial activity. *Bioorg. Med. Chem. Lett.* 2013, 23, 1537–1543. [CrossRef]

21. Kawatkar, S.P.; Keating, T.A.; Olivier, N.B.; Breen, J.N.; Green, O.M.; Guler, S.Y.; Hentemann, M.F.; Loch, J.T.; McKenzie, A.R.; Newman, J.V.; et al. Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase: Structure–Activity Relationships and Chiral Preference of a New Hydrophobic Binding Region. *J. Med. Chem.* 2014, 57, 4584–4597. [CrossRef]

22. Ke, P.-Y.; Kuo, Y.-Y.; Hu, C.-M.; Chang, Z.-F. Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. *Genes Dev.* 2005, 19, 1920–1933. [CrossRef]

23. Ahmad, S.I.; Kirk, S.H.; Eisenatark, A. Thymine metabolism and thyminless death in prokaryotes and eukaryotes. *Annu. Rev. Microbiol.* 1998, 52, 591–625. [CrossRef]

24. Hernandes, M.Z.; Cavalcanti, S.M.; Moreira, D.R.; de Azevedo Junior, W.F.; Leite, A.C. Halogen atoms in the modern medicinal chemistry: Hints for the drug design. *Curr. Drug Targets* 2010, 11, 303–314. [CrossRef]

25. WHO 2021 AWaRe Classification. Available online: https://www.who.int/publications/i/item/2021-aware-classification (accessed on 22 June 2022).

26. Kompis, I.; Wick, A. Cheminform Abstract: Synthesis of 4-Halo-Substituted Analogs of Trimethoprim. *Chem. Inf.-Dienst.* 1978, 9. [CrossRef]

27. Cosmi, E.V.; Cantini, L.; Monici Preti, P.A.; Di Renzo, G.C.; Abate, F.; Balsotti, G.; Cirese, E.; Indraccolo, R. Efficacy and tolerability of brodropriom at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: Comparative study vs. pefloxacin. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 1996, 64, 207. [CrossRef]

28. Lovell, F.M. The Structure of a Bromine-Rich Marine Antibiotic. *J. Am. Chem. Soc.* 2006, 128, 4510–4511. [CrossRef]

29. Fehér, D.; Barlow, R.; McAtee, J.; Hemseidt, T.K. Highly brominated antimicrobial metabolites from a marine *Pseudoalteromonas* sp. *J. Nat. Prod.* 2010, 73, 1963–1966. [CrossRef]

30. Li, C.; Bao, W.; Zhang, H.; Lyu, Z.; Chen, Y.; Guo, Z. Discovery of Brominated Alboflavusins with Anti-MRSA Activities. *Front. Microbiol.* 2021, 12, 641025. [CrossRef]

31. Raimondi, M.V.; Cascioferro, S.; Schillaci, D.; Petruso, S. Synthesis and antimicrobial activity of new bromine-rich pyrrole derivatives related to monodeoxypseudopteroin. *Eur. J. Med. Chem.* 2006, 41, 1439–1445. [CrossRef]

32. Labrière, C.; Elumalai, V.; Staffansson, J.; Cervin, G.; Le Norcy, T.; Denardou, H.; Ribeiro, D.; Barlow, R.; McAtee, J.; Hemseidt, T.K. Highly brominated antimicrobial metabolites from a marine *Pseudoalteromonas* sp. *J. Nat. Prod.* 2010, 73, 1963–1966. [CrossRef]

33. Chiarini, P.; Cosmi, E.; Rebiere, C.; Elumalai, V.; Staffansson, J.; Cervin, G.; Le Norcy, T.; Denardou, H.; Ribeiro, D.; Barlow, R.; McAtee, J.; Hemseidt, T.K. Highly brominated antimicrobial metabolites from a marine *Pseudoalteromonas* sp. *J. Nat. Prod.* 2010, 73, 1963–1966. [CrossRef]

34. Martínez-Botella, G.; Breen, J.N.; Duffy, J.E.S.; Dumas, J.; Geng, B.; Gowers, I.K.; Green, O.M.; Guler, S.Y.; Hentemann, M.F.; Hernandez-Juan, F.A.; et al. Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK). *J. Med. Chem.* 2012, 55, 10010–1012. [CrossRef]

35. Mardirosian, M.; Rubini, M.; Adano, M.F.A.; Socchi, M.; Saviano, M.; Tossi, A.; Gennaro, R.; Caporale, A. Natural and Synthetic Halogenated Amino Acids—Structural and Bioactive Features in Antimicrobial Peptides and Peptidomimetics. *Molecules* 2021, 26, 7401. [CrossRef]

36. Melón, N.; Nielsen, E.R.; Sørensen, K.B.; Prabhala, B.K.; Hansen, P.R.; Lund, R.; Barron, A.E.; Jønssen, H. Halogenation as a tool to tune antimicrobial activity of peptoids. *Sci. Rep.* 2020, 10, 14805. [CrossRef]

37. Metrangolo, P.; Neurich, H.; Pilati, T.; Resnati, G. Halogen Bonding Based Recognition Processes: A World Parallel to Hydrogen Bonding. *Acc. Chem. Res.* 2005, 38, 386–395. [CrossRef]

38. Wilcken, R.; Zimmermann, M.O.; Lange, A.; Joerg, A.C.; Bodecker, F.M. Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology. *J. Med. Chem.* 2013, 56, 1363–1388. [CrossRef]

39. Blindheim, F.H.; Olsen, C.E.; Krogh Soggaard, C.; Otterlei, M.; Sundby, E.; Hoff, B.H. Synthetic Strategies towards Imidazopyridinones and 7-Azaaconoides and their Evaluation as Antibacterial Agents. *Eur. J. Org. Chem.* 2021, 2021, 2701–2712. [CrossRef]

40. CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard*, 9th ed.; CLSI; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2012.

41. Chaudhary, S.K.; Jeayakantham, J.; Sekar, K. Structural and functional roles of dynamically correlated residues in thymidylate kinase. *Acta Cryst. D Struct Biol.* 2018, 74, 354–351. [CrossRef]

42. Kotaka, M.; Dhaliwal, B.; Ren, J.; Nichols, C.E.; Angell, R.; Locker, M.; Hawkins, A.R.; Stammers, D.K. Structures of S. aureus thymidylate kinase reveal an atypical active site configuration and an intermediate conformational state upon substrate binding. *Protein Sci.* 2006, 15, 774–784. [CrossRef]

43. Sundby, E.; Han, J.; Kaspersen, S.J.; Hoff, B.H. In vitro baselining of new pyrrolopyrimidine-EGFR-TK inhibitors with Erlotinib. *Eur. J. Pharm. Sci.* 2015, 80, 56–65. [CrossRef]

44. Bugge, S.; Buene, A.F.; Jurisch-Yasaki, N.; Moen, I.U.; Skjønsfjell, E.M.; Sundby, E.; Hoff, B.H. Extended Structure–Activity Study of Thienopyrimidine-Based EGFR Inhibitors with Evaluation of Drug-Like Properties. *Eur. J. Med. Chem.* 2016, 107, 255–274. [CrossRef]
45. Kaspersen, S.J.; Sørum, C.; Willassen, V.; Fuglseth, E.; Kjøbli, E.; Bjørkøy, G.; Sundby, E.; Hoff, B.H. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines. *Eur. J. Med. Chem.* 2011, 46, 6002–6014. [CrossRef]

46. Reiersølmoen, A.C.; Han, J.; Sundby, E.; Hoff, B.H. Identification of fused pyrimidines as interleukin 17 secretion inhibitors. *Eur. J. Med. Chem.* 2018, 155, 562–578. [CrossRef]

47. Traxler, P.; Bold, G.; Brill, W.K.-D.; Frei, J. Preparation of 7H-Pyrrolo[2,3-d]Pyrimidines as Tyrosine Protein Kinase Inhibitors. WO9702266, 23 January 1997.

48. Kaspersen, S.J.; Sundby, E.; Charnock, C.; Hoff, B.H. Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to *Tetrahymena*. *Bioorg. Chem.* 2012, 44, 35–41. [CrossRef]

49. Pollok, B.A.; Hamman, B.D.; Rodems, S.M.; Makings, L.R. Optical Probes and Assays. WO2000066766, 09 November 2000.

50. Liang, X.; Huang, Y.; Zang, J.; Gao, Q.; Wang, B.; Xu, W.; Zhang, Y. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. *Bioorg. Med. Chem.* 2016, 24, 2660–2672. [CrossRef]

51. Klečka, M.; Poštová Slavětínská, L.; Hocek, M. Modification of Pyrrolo[2,3-d]pyrimidines by C–H Borylation Followed by Cross-Coupling or Other Transformations: Synthesis of 6,8-Disubstituted 7-Deazapurine Bases. *Eur. J. Org. Chem.* 2015, 2015, 7943–7961. [CrossRef]

52. Bugge, S.; Kaspersen, S.J.; Sundby, E.; Hoff, B.H. Route selection in the synthesis of C-4 and C-6 substituted thienopyrimidines. *Tetrahedron* 2012, 68, 9226–9233. [CrossRef]

53. Bugge, S.; Skjønsfjell, E.M.; Willumsen, F.B.; Sundby, E.; Hoff, B.H. Improved and Scalable Preparation of 6-Bromo-4-Chlorothieno[2,3-d]Pyrimidine. *Chem. Heterocycl. Compd.* 2014, 50, 1177–1187. [CrossRef]